Recent Updates
Recently added Catalysts

Plavix film-coated

Phase 1

Bioequivalence | Small molecule | Other |Ligand Pharmaceuticals Incorporated|Last Updated: Nov 30, 2023

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedCONTROLLEDBiomarker
Total Trials1
Total Enrollment60
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT05934799Bioequivalence Study of Two Formulations of Clopidogrel Film-coated Tablets 75 mg in Healthy Male Subjects Under Fasting ConditionsPHASE1 COMPLETED 60Jun 16, 2023Oct 10, 2023Nov 30, 20231 Russia
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Cmax of сlopidogrel in plasma after administration of the test and the reference products.
Time points 0.00 (prior to each drug administration) and 10 min, 15 min, 20 min, 30 min, 40 min, 50 min, 1.00, 1.15, 1.30, 2.00, 2.30, 3.00, 4.00, 6.00, 8.00, 10.00 12.00, 16.00, 24.00 hours after each drug administration.

Maximum observed concentration in plasma.

AUC0-t of сlopidogrel in plasma after administration of the test and the reference.
Time points 0.00 (prior to each drug administration) and 10 min, 20 min, 30 min, 40 min, 50 min, 1.00, 1.15, 1.30, 2.00, 2.30, 3.00, 4.00, 6.00, 8.00, 10.00 12.00, 16.00, 24.00 hours after each drug administration.

Cumulative area under the concentration time curve calculated from 0 to time of last observed quantifiable concentration (TLQC) using the linear trapezoidal method.

Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingSINGLE
ModelCROSSOVER
PurposeOTHER
Treatment Arms
ArmTypeDescription
Sequence TROTHER30 subjects assigned to the sequence TR will receive a single 75 mg dose of the test product Clopidogrel (1 x 75 mg film-coated tablet), marked as T in the sequence, in Period 1 and Period 3, and a single 75 mg dose of the reference product Plavix® (1 x 75 mg film-coated tablet), marked as R in the sequence, in period 2 and Period 4. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
Sequence RTOTHER30 subjects assigned to the sequence RT will receive a single 75 mg dose of the reference product Plavix® (1 x 75 mg tablet), marked as R in the sequence, in Period 1 and Period 3 and a single 75 mg dose of the test product Clopidogrel (1 x 75 mg tablet), marked as T in the sequence, in period 2 and Period 4. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
Interventions
NameTypeDescription
Clopidogrel film-coated tablet 75 mgDRUGClopidogrel is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 75 mg of clopidogrel.
Plavix® film-coated tablet 75 mgDRUGPlavix® is manufactured by Sanofi Winthrop Industry, France; holder RU: Sanofi-Aventis Group S.A., France. Each tablet contains 75 mg of clopidogrel.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 45 Years
SexMALE
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: 1. Healthy european men aged between 18 to 45 years 2. signed informed consent 3. Subjects having no clinically significant medical history and no clinically significant abnormalities in general physical examination, laboratory assessments and imaging studies 4. Body mass index ...

Countries:Russia
Unlock Eligibility Criteria